PharmaPoint: Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023 - New Market Report

GlobalData has released its new PharmaPoint Country Evaluation report, "PharmaPoint: Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Full Report Details at
- http://www.fastmr.com/prod/944660_pharmapoint_colorectal_cancer_japan_drug_forecast.aspx?afid=301

Japan represents the second-largest market for CRC across the countries covered in this report. Japan is a major CRC market, due to the high incidence of the disease and high drug treatment rates. Increased sales of CRC therapies over the forecast period will be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastases patients, and the launch of expensive new therapies that provide further treatment options for patients in later-line settings, replacing cheaper generic chemotherapy only regimens.

Scope

* Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Japan from 2013-2023.
* Analysis of the impact of key events as well the drivers and restraints affecting the Japan CRC market.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for CRC
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2013-2023 in Japan.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Colorectal Cancer - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: Colorectal Cancer - China Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023